



Cellumen Selected as Signature Partner of Drug Safety Executive Council

Company is One of Only Eight Technology and Service Providers Chosen for Discovery Toxicology

PITTSBURGH--([BUSINESS WIRE](#))--[Cellumen, Inc.](#), a discovery toxicology company, today announced the company has been selected by the [Drug Safety Executive Council](#) (DSEC) as one of eight [Signature Partners](#) working to improve drug safety by addressing industry challenges and regulatory practices.

As a [Signature Partner](#), [Cellumen](#) will work with the DSEC to promote ideas, further initiatives, and implement technologies that will ultimately improve the overall economics of R&D. In addition, Cellumen will use its [CellCiphr® CSB™ Toxicity Profiling Services](#) to identify toxic responses for DSEC members. The Signature Partnership is reconsidered annually.

“We’re honored to serve as one of DSEC’s Signature Partners and join such an esteemed group of colleagues,” says Donald Taylor, Senior Director of Marketing and Corporate Development at Cellumen. “Cellumen’s vision is to improve healthcare by setting the standard for discovery toxicology solutions, and we are excited to bring our cellular systems biology services to the DSEC’s more than 1,300 members to foster safer and more profitable drug development.”

Cellumen’s CellCiphr® CSB™ Toxicity Profiling Services can identify toxic compounds in late primary screening through early pre-clinical phases, before entering expensive pre-clinical testing where the pharmaceutical industry is losing millions of dollars from drugs that do not meet the FDA’s safety requirements. By integrating optimal cells, panels of functional biomarkers and classifier software, CellCiphr is able to create a Safety Risk Index for compounds, and help researchers predict potential rodent or human toxicity earlier than ever before.

“We’re pleased to welcome Cellumen as a Signature Partner,” says Eric Glazer, Managing Director of the Drug Safety Executive Council. “We encourage the collaboration of our members and partners to advance the progress of drug safety through dialogue and information sharing. Cellumen will add greatly to this conversation.”

The DSEC is a non-profit peer-to-peer membership formed in cooperation with various heads of global safety for R&D leaders to work collaboratively and advance the progress of drug development. DSEC membership is limited to employees of companies that advance and transform the current state of drug development in both small and large molecule pharmaceuticals.

About Cellumen

Cellumen is the leading innovator in cellular systems biology (CSB™) solutions providing the most accurate predictions of drug efficacy and safety, thus reducing failure rates and cutting development costs. Cellumen’s CSB solutions are driving Discovery Toxicology by addressing the full complexity of disease and safety. Leading global organizations, such as the Mayo Clinic, Hamamatsu Photonics K.K., the EPA, FDA, NIH and top pharmaceutical companies, partner with Cellumen. Cellumen is a partner company of [Safeguard Scientifics](#). Other investors include [Novitas Capital](#), the [Pittsburgh Life Sciences Greenhouse](#) and [Innovation Works](#). For more information about Cellumen, please visit www.cellumen.com.